Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.
about
International Consensus Document (ICON): Common Variable Immunodeficiency DisordersRecognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic reviewA review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin.Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiencyCurrent perspectives on common variable immunodeficiency (CVID).Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.Immunoglobulin replacement treatment by rapid subcutaneous infusion.Immunoglobulin therapy: history, indications, and routes of administration.Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies.Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.Subcutaneous immunoglobulin: opportunities and outlook.Indications and safety of intravenous and subcutaneous immunoglobulin therapy.Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.Modern management of primary B-cell immunodeficiencies.Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.Overview of routes of IgG administration.Why I use subcutaneous immunoglobulin (SCIG).Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.Hizentra for the treatment of primary immunodeficiency.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.From identification of the BTK kinase to effective management of leukemia.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
P2860
Q26777304-A9D6C170-2983-49B3-8362-F2D636807ACEQ28755847-76FA03E6-4D1C-48A9-A401-5FC81396421CQ33399594-EA6981EC-222B-4D55-BC3B-7E3D3ABB4DE5Q33417506-522D4BDD-DFB7-494D-A3B3-299164D47A77Q33603438-F49840BE-0970-4709-BDCB-9447800E56E4Q33635013-E08168AF-77DD-40ED-A67B-96009F123DA1Q33692418-7BEC8297-D842-4563-A84B-538FBBFFB04FQ33878939-2DE86D31-DD1F-415C-8720-E155601CBDD4Q34112793-435F8A7C-40B7-4DBB-A6A1-DDE3719D9813Q34255299-14B5D523-61A5-4FA6-AA21-8F72F781D87DQ34627045-0691F0F1-EB0B-4247-AE01-C8041E3C2C51Q35259959-B45AAA8D-CB37-45CE-96D0-A41745D68CBDQ35685969-AEB14D53-BD03-49B8-885E-BBE48EB63F6AQ35905557-614341A0-6625-4722-8F03-3E045388AC18Q36121067-EBC597A9-2CF4-4012-B5D5-9AADC2B72B35Q36196688-27F4720A-D6E1-40BE-A866-F7773958B1A3Q36884511-84813C57-ECE2-44E4-A0A7-2943D2C8928EQ37031111-F02B1083-40C4-4B3A-8555-88EA6B6F83FEQ37083973-4E019048-4328-4F90-8D01-B5497CA52222Q37246362-3935E8EC-B539-4C70-A393-63929BABC905Q37514512-11BBAD89-95EE-448F-B365-34B81AB03835Q37626132-536B4273-0CE7-46E2-9DF5-D8A668762B12Q37877259-BCF67E52-B75D-4F04-B8D0-AD677D236C18Q37929510-C33FA112-C17F-4CBE-A2EC-70DD92013AEFQ37962045-7717E3A7-8677-4912-995C-B2B60067C4A9Q38021422-9B05ED79-4482-4FFF-B742-6D02449AD9AAQ38065205-8BDBC684-1BD3-4CD9-8272-6FC31A8A50DBQ38066415-CF250CB8-847F-4C53-A607-035AFA546C3FQ38069527-05ED3A1D-A928-4098-B987-5FDB3B9D0444Q38122120-A9A33FBE-FA40-4205-8977-5EE7D93059F3Q38152428-F2C67717-25B6-4056-B8E3-5BBD4ADFA5AFQ38245612-5BD053B6-E9E3-476C-92CA-CD550C9991F9Q38266635-60CFA403-D379-474E-AB7A-0757C9388EC7Q38390889-E25F9383-1DF6-46C5-9C57-D7DED0CC6D19Q38420971-2B1A2B22-90DC-4494-825F-44DDA7F153EBQ38661420-AB2CF902-F8D5-4BF8-A333-EADA483CD356Q38744512-AD623098-319A-462C-8EE8-D6A7263D5CE2Q38817591-97003EE1-B4EE-427B-95DB-A6EFC16AD6F2Q39217483-2D4CEA94-2596-47F8-91D0-87A112759505Q39370917-4ED40B7F-0C2C-4527-BF13-23DCC8F86F67
P2860
Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@en
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@nl
type
label
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@en
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@nl
prefLabel
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@en
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@nl
P1433
P1476
Home treatment of hypogammaglo ...... mmaglobulin by rapid infusion.
@en
P2093
P304
P356
10.1016/0140-6736(91)90147-H
P407
P577
1991-07-01T00:00:00Z